Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$6.06 USD
+0.24 (4.12%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $5.95 -0.11 (-1.82%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.06 USD
+0.24 (4.12%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $5.95 -0.11 (-1.82%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Zacks News
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
by Zacks Equity Research
Dr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302.
Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Coya Therapeutics, Inc. (COYA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
by Zacks Equity Research
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.